^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) + albumin-bound paclitaxel (Tubulin inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
HRS-4642 combined with gemcitabine and albumin-bound paclitaxel for neoadjuvant and adjuvant treatment of pancreatic cancer: an xploratory clinical study.
Excerpt:
...1) Male and female subjects aged 18-75 years (including 18 and 75 years); 2) Pancreatic ductal adenocarcinoma confirmed by pathology (histology) or cytology, identified as a carrier of KRAS G12D mutation; 3) Borderline resectable pancreatic cancer as defined by the NCCN guidelines for imaging assessment, locally advanced pancreatic cancer as potentially resectable, and high-risk resectable pancreatic cancer as assessed by the investigators. ...
Trial ID:
Source:
Title:
A Single-Center Phase II Study to Evaluate the Efficacy of Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer Based on Circulating Tumor DNA Detection
Excerpt:
...Disease-free Survival - Disease-free Survival; Overall Survival - Overall Survival; the mutation of ctDNA KRAS - the mutation of ctDNA KRAS; CT/MR - CT/MR; Blood routine - Blood routine; Biochemistry - Biochemistry; ion - ion; Tumor markers - Tumor markers; Blood clotting function - Blood clotting function...
Trial ID:
Less C2 evidence
Source:
Title:
KRAS mutation detection and cfDNA in liquid biopsy as prognostic factors in pancreatic adenocarcinoma.
Published date:
05/26/2022
Excerpt:
We included 33 PDAC patients with a median age of 66.1 years old, 57% were women. All of them were treated with gemcitabine and Nab-paclitaxel….Median overall survival (OS) was 10.5 months in the KRAS detected group compared with 22.6 months in the KRAS non-detected group (HR for death 4.70; confidence interval (CI) 1.70-12.98, p-value 0.002).
DOI:
10.1200/JCO.2022.40.16_suppl.e16302